1. Home
  2. CELC vs VREX Comparison

CELC vs VREX Comparison

Compare CELC & VREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • VREX
  • Stock Information
  • Founded
  • CELC 2011
  • VREX 2016
  • Country
  • CELC United States
  • VREX United States
  • Employees
  • CELC N/A
  • VREX N/A
  • Industry
  • CELC Medical Specialities
  • VREX Industrial Machinery/Components
  • Sector
  • CELC Health Care
  • VREX Technology
  • Exchange
  • CELC Nasdaq
  • VREX Nasdaq
  • Market Cap
  • CELC 327.3M
  • VREX 297.3M
  • IPO Year
  • CELC 2017
  • VREX N/A
  • Fundamental
  • Price
  • CELC $10.15
  • VREX $6.88
  • Analyst Decision
  • CELC Strong Buy
  • VREX Strong Buy
  • Analyst Count
  • CELC 6
  • VREX 2
  • Target Price
  • CELC $30.17
  • VREX $22.50
  • AVG Volume (30 Days)
  • CELC 190.9K
  • VREX 555.0K
  • Earning Date
  • CELC 05-14-2025
  • VREX 05-08-2025
  • Dividend Yield
  • CELC N/A
  • VREX N/A
  • EPS Growth
  • CELC N/A
  • VREX N/A
  • EPS
  • CELC N/A
  • VREX N/A
  • Revenue
  • CELC N/A
  • VREX $827,500,000.00
  • Revenue This Year
  • CELC N/A
  • VREX $4.16
  • Revenue Next Year
  • CELC N/A
  • VREX $3.71
  • P/E Ratio
  • CELC N/A
  • VREX N/A
  • Revenue Growth
  • CELC N/A
  • VREX N/A
  • 52 Week Low
  • CELC $7.58
  • VREX $6.97
  • 52 Week High
  • CELC $19.77
  • VREX $17.46
  • Technical
  • Relative Strength Index (RSI)
  • CELC 46.58
  • VREX 32.29
  • Support Level
  • CELC $9.64
  • VREX $8.09
  • Resistance Level
  • CELC $10.80
  • VREX $8.71
  • Average True Range (ATR)
  • CELC 0.66
  • VREX 0.54
  • MACD
  • CELC -0.06
  • VREX 0.11
  • Stochastic Oscillator
  • CELC 25.25
  • VREX 5.71

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About VREX Varex Imaging Corporation

Varex Imaging Corp designs and manufactures X-ray imaging components. It operates in two segments Medical and Industrial. The Medical segment, which is the key revenue driver, designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, generators, and heat exchangers among other products. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high-voltage connectors, and coolers. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA) and the rest from the Americas and Asia Pacific region.

Share on Social Networks: